XM no presta servicios a los residentes de Estados Unidos de América.

XM no presta servicios a los residentes de Estados Unidos de América.
B
B

BayerAG

Noticias

Reuters - Hace 19 horas

Bayer, others defeat US farmers' chemical price-fixing lawsuit

Bayer, others defeat US farmers' chemical price-fixing lawsuit By Mike Scarcella Sept 16 (Reuters) - A U.S. judge has dismissed a lawsuit accusing agriculture giants Bayer, Corteva, Syngenta and others of conspiring with wholesalers and retail outlets to fix prices for seeds and crop protection chemicals, causing farmers to pay higher prices. St. Louis-based U.S.
B
B
C
Reuters - Hace 1 día

Bayer AG Says Darolutamide Plus Adt Significantly Reduced Risk Of Radiological Progression Or Death Compared To Placebo Plus Adt In Patients With Mhspc

BRIEF-Bayer AG Says Darolutamide Plus Adt Significantly Reduced Risk Of Radiological Progression Or Death Compared To Placebo Plus Adt In Patients With Mhspc Bayer AG BAYGn.DE : BAYER AG SAYS DAROLUTAMIDE PLUS ADT SIGNIFICANTLY REDUCED RISK OF RADIOLOGICAL PROGRESSION OR DEATH COMPARED TO PLACEBO PLUS ADT IN PATIENTS WITH MHSPC Source text for Eiko
B
Reuters - Hace 5 días

Jury rules in favor of Bayer's Monsanto in Philadelphia trial over Roundup

Jury rules in favor of Bayer's Monsanto in Philadelphia trial over Roundup Sept 11 (Reuters) - Bayer's BAYGn.DE Monsanto unit said on Wednesday that a Philadelphia Court jury reached a verdict in the Young Roundup product liability trial in their favor. Bayer bought Monsanto for $63 billion in 2018, and has faced extensive and costly litigation over whether Monsanto's Roundup weed killer causes cancer.
B
Reuters - Hace 5 días

Bayer Says Jury Finds In Favor Of Monsanto In Philadelphia Trial

BRIEF-Bayer Says Jury Finds In Favor Of Monsanto In Philadelphia Trial Sept 11 (Reuters) - Bayer AG BAYGn.DE : JURY FINDS IN FAVOR OF MONSANTO IN PHILADELPHIA TRIAL BAYER AG: JURY REACHED VERDICT IN YOUNG ROUNDUP PRODUCT LIABILITY TRIAL BEFORE JUDGE ANGELO FOGLIETTA IN PHILADELPHIA COURT OF COMMON PLEAS. BAYER AG - WILL CONTINUE SUPPORTING LEGISLAT
B
Reuters - Hace 1 semana

Bayer Issues 750 Million Euro Hybrid Bond

BRIEF-Bayer Issues 750 Million Euro Hybrid Bond Sept 10 (Reuters) - BAYER AG BAYGn.DE : ISSUES 750 MILLION EURO HYBRID BOND SINGLE TRANCHE WITH A NON-CALL PERIOD OF 5.25 YEARS, COMBINED WITH A TENDER OFFER FOR ONE OF BAYER’S EXISTING HYBRID BONDS BAYER INTENDS TO LIST THE HYBRID BONDS ON THE LUXEMBOURG STOCK EXCHANGE THE PROCEEDS WILL BE USED FOR
B
Reuters - Hace 1 semana

European companies cut jobs as economy sputters

RPT-FACTBOX-European companies cut jobs as economy sputters Repeats with no changes to text to add 'Factbox' tag in headline Sept 10 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some of the layoffs announced since the start of June: BANKS * DNB DNB.OL : The Norwegian lender said on Sept.
B
I
U
V
U
Reuters - Hace 1 semana

European companies cut jobs as economy sputters

European companies cut jobs as economy sputters Adds DNB Sept 10 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some of the layoffs announced since the start of June: BANKS * DNB DNB.OL : The Norwegian lender said on Sept. 10 it would cut the equivalent of 500 full-time jobs over the next six months, as it prepares for lower interest rates and tougher competition ahead.
B
I
U
V
U
Reuters - Hace 1 semana

Bayer: Analysis From HF Reveals Patients Receiving Finerenone Have Reduced Risk Of New-Onset Diabetes

BRIEF-Bayer: Analysis From FINEARTS-HF Reveals Patients Receiving Finerenone Have Reduced Risk Of New-Onset Diabetes Sept 10 (Reuters) - BAYER AG BAYGn.DE : NEW SUBGROUP ANALYSIS FROM FINEARTS-HF REVEALED PATIENTS WITH HEART FAILURE AND A LEFT VENTRICULAR EJECTION FRACTION OF ≥40% RECEIVING FINERENONE HAD A REDUCED RISK OF NEW-ONSET DIABETES Furt
B
Reuters - Hace 1 semana

Bayer Reports Preliminary Efficacy Results for BAY 2927088 in Phase I/ 01 Study

BRIEF-Bayer Reports Preliminary Efficacy Results for BAY 2927088 in Phase I/ II SOHO-01 Study Sept 10 (Reuters) - BAYER AG BAYGn.DE : SAID ON MONDAY: NEW RESULTS FOR INVESTIGATIONAL AGENT BAY 2927088 IN HER2-MUTANT NON-SMALL CELL LUNG CANCER PRESENTED ENCOURAGING RESULTS FROM EXPANSION PART OF ONGOING PHASE I/II SOHO-01 STUDY EVALUATING THE SAFETY
B
Reuters - Hace 1 semana

Bayer's Eye Drug Pre-Filled Syringes Approved In EU

BRIEF-Bayer's Eye Drug Pre-Filled Syringes Approved In EU Sept 9 (Reuters) - Bayer AG BAYGn.DE : EYLEA™ 8 MG PRE-FILLED SYRINGE APPROVED IN EU GERMANY WILL BE ONE OF FIRST MARKETS TO LAUNCH NEW PRE-FILLED SYRINGE Further company coverage: BAYGn.DE (Gdansk Newsroom)
B
Reuters - Hace 2 semanas

Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio

BRIEF-Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio Sept 4 (Reuters) - BAYER AG BAYGn.DE WILL PRESENT PRIMARY RESULTS FROM THE PHASE III ARANOTE TRIAL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) FOR NUBEQA(®)(DAROLUTAMIDE) AS A LATE-BREAKING ORAL PRESENTATION WILL PRESENT PRIMARY RESULTS FROM THE EUROPEAN O
B
Reuters - Hace 2 semanas

VW row flags Germany’s creaking corporate model

BREAKINGVIEWS-VW row flags Germany’s creaking corporate model The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Pierre Briancon BERLIN, Sept 5 (Reuters Breakingviews) - A company whose chief financial officer says it only has “one, maybe two” years to turn around its core brand must have done something wrong.
B
B
T
V
Reuters - Hace 2 semanas

Bayer To Unveil New Data From Its Phase III Oasis 3 Long-Term Study Of Elinzanetant

BRIEF-Bayer To Unveil New Data From Its Phase III Oasis 3 Long-Term Study Of Elinzanetant Sept 4 (Reuters) - BAYER AG BAYGn.DE : TO UNVEIL NEW DATA FROM ITS PHASE III OASIS 3 LONG-TERM STUDY OF ELINZANETANT IN TREATMENT OF VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE BAYER WILL PRESENT DETAILED RESULTS SEPTEMBER 10 - 14 Further company coverage: [B
B
Reuters - Hace 2 semanas

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds Telia Sept 4 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some of the layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * PKP CARGO PKPP.WA : Poland's largest freight co
B
B
B
C
I
N
T
T
U
V
B
U
Reuters - Hace 2 semanas

US will still pay at least twice as much after negotiating drug prices

UPDATE 1-US will still pay at least twice as much after negotiating drug prices U.S. pays higher drug prices, gets priority access Medicare's negotiated prices most significant for drugs with little competition Goal is to balance affordability and innovation Updates first graphic to align colors representing countries with second graphic By Deena Beasley Sept 3 (Reuters) - The U.S.
A
A
B
N
P
Reuters - Hace 2 semanas

Bayer: Bluerock Gets FDA Clearance Of Application For Photoreceptor Diseases Treatment

BRIEF-Bayer: Bluerock Gets FDA Clearance Of Application For Photoreceptor Diseases Treatment Sept 3 (Reuters) - Bayer AG BAYGn.DE : BLUEROCK THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR INVESTIGATIONAL IPSC-DERIVED CELL THERAPY OPCT-001 FOR TREATMENT OF PRIMARY PHOTORECEPTOR DISEASES Further company coverage: [BAYGn.DE] (Gdansk Newsr
B
Reuters - Hace 2 semanas

US will still pay at least twice as much after negotiating drug prices

ANALYSIS-US will still pay at least twice as much after negotiating drug prices U.S. pays higher drug prices, gets priority access Medicare's negotiated prices most significant for drugs with little competition Goal is to balance affordability and innovation By Deena Beasley Sept 3 (Reuters) - The U.S. government's first-ever negotiated prices for prescription drugs are still on average more than double, and in some cases five times, what drugmakers have agreed to in four other high-income count
A
A
B
N
P
Reuters - Hace 2 semanas

Bayer rises after positive kidney drug study in heart failure

CORRECTED-BUZZ-Bayer rises after positive kidney drug study in heart failure Corrects trial name in 2nd bullet; updates share performance in 1st and 5th bullet ** Shares in Bayer BAYGn.DE rise 0.6% after the German firm said its kidney drug Kerendia helped patients avoid complications from a common form of heart failure ** The late-stage FINEARTS-H
B
G
Reuters - Hace 2 semanas

Bayer Shares Finerenone Update

BRIEF-Bayer Shares Finerenone Update Sept 2 (Reuters) - BAYER AG BAYGn.DE : SAID ON SUNDAY FINERENONE SHOWED SIGNIFICANT IMPROVEMENT IN CARDIOVASCULAR OUTCOMES IN ADULTS WITH COMMON FORM OF HEART FAILURE WITH HIGH UNMET MEDICAL NEED Source text for Eikon: ID:nNDL72qgt8 Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B
Reuters - Hace 3 semanas

Europe's STOXX 600 corporate earnings week ahead

DIARY-Europe's STOXX 600 corporate earnings week ahead Aug 30 (Reuters) - Diary of Europe's STOXX 600 (.STOXX) corporate earnings for the week ahead EUROPE'S STOXX 600 EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 02-Sep-2024 09:00 BAYGn.DE Bayer AG Bayer AG Investor Webinar to Discuss Results from FINEARTS-HFP 02-Sep-2024 09:00 PZU.WA Powszechny Zaklad Ubezpieczen SA Half Year 2024 Powszechny Zaklad Ubezpieczen SA Investor Chat (Polish) 03-Sep-2024 NTS BKWB.S BKW AG Half Year
A
B
B
B
H
R
S
D
S

Condiciones

Activos populares

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Advertencia de riesgo: Su capital está en riesgo. Los productos apalancados pueden no ser adecuados para todos. Por favor, tenga en cuenta nuestra Declaración de riesgos.